2019
DOI: 10.1007/s00580-019-03028-4
|View full text |Cite
|
Sign up to set email alerts
|

Fasting hyperglycaemia, glucose intolerance and pancreatic islet necrosis in albino rats associated with subchronic oral aluminium chloride exposure

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 22 publications
0
1
0
Order By: Relevance
“…Ingestion of aluminium phosphide pellets was reported to induce acute pancreatitis in one patient (Verma et al, 2007). Rats had moderate pancreatic islet necrosis after intermediate oral exposure (50 mg/kg for 28 days) to Al chloride ( Figure 9) which was associated with impaired fasting blood glucose and impaired oral glucose tolerance (Igwenagu, 2017;Igwenagu et al, 2019). Rats treated intra-peritoneally with Al chloride at 10 mg/kg for 30 days had significantly increased fasting blood glucose, serum insulin level and insulin resistance index on days 10 and 20 of treatment, but as treatment progressed to day 30, serum insulin level had decreased, indicating that pancreatic β-cell function decreased as pancreatic damage occurred with progression of treatment (Wei et al, 2018).…”
Section: Hepato-renal and Pancreatic Effectsmentioning
confidence: 99%
“…Ingestion of aluminium phosphide pellets was reported to induce acute pancreatitis in one patient (Verma et al, 2007). Rats had moderate pancreatic islet necrosis after intermediate oral exposure (50 mg/kg for 28 days) to Al chloride ( Figure 9) which was associated with impaired fasting blood glucose and impaired oral glucose tolerance (Igwenagu, 2017;Igwenagu et al, 2019). Rats treated intra-peritoneally with Al chloride at 10 mg/kg for 30 days had significantly increased fasting blood glucose, serum insulin level and insulin resistance index on days 10 and 20 of treatment, but as treatment progressed to day 30, serum insulin level had decreased, indicating that pancreatic β-cell function decreased as pancreatic damage occurred with progression of treatment (Wei et al, 2018).…”
Section: Hepato-renal and Pancreatic Effectsmentioning
confidence: 99%